Please login to the form below

Not currently logged in

UK diabetes spend to reach £16.9bn by 2035

In 25 years 17 per cent of NHS budget to go on the condition
By 2035 the NHS will increase its spending on diabetes from £9.8bn to £16.9bn, according to a new report published in the journal Diabetic Medicine.

Authored by York Health Economic Consortium and in partnership with Diabetes UK, the diabetes research charity JDRF and Sanofi Diabetes, the Impact Diabetes report also suggests that the cost of treating diabetes complications will double, from £7.7bn to 13.5bn during this period.

According to the report, 79 per cent of current NHS diabetes spending goes on complications, however, investing in 'checks and services' could help reduce this cost.

“This report shows that without urgent action, the already huge sums of money being spent on treating diabetes will rise to unsustainable levels that threaten to bankrupt the NHS,” said Barbara Young, chief executive of Diabetes UK.

“But the most shocking part of this report is the finding that almost four-fifths of the NHS diabetes spending goes on treating complications that in many cases could have been prevented.

“The failure to do more to prevent these complications is both a tragedy for the people involved and a damning indictment of the failure to implement the clear and recommended solutions. Unless the Government and the NHS start to show real leadership on this issue, this unfolding public health disaster will only get worse”.

JDRF commended the report for having separately listed the causes and costs of Type 1 diabetes, against the challenges and costs of Type 2. They also called for more research to be done to assist the economic impact on families, the NHS and the economy.

Sanofi, who earlier this year invested $3.1m into diabetes research with the University of California, have said that they plan to continue examining the cost impact of adopting NICE guidelines across the UK, which aims to use effective management in order to reduce the cost burden of diabetes.

8th August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Black Swan Analysis

We are experts in pharmaceutical forecasting with access to proprietary databases of disease-specific patient populations. We understand the limits of...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...